ClinicalTrials.gg
WithdrawnNCT04145193Updated Sep 21, 2020

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

A Phase 2 interventional study of Standard of Care - mFOLFOX6 and E1 - mFOLFOX and durvalumab in Microsatellite-stable Colorectal Cancer, sponsored by MedImmune LLC. Withdrawn. Open to participants aged 18 Years to 101 Years. Per ClinicalTrials.gov, last updated 2020-09-21.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study withdrawn prior to enrollment due to changing standard of care landscape.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 101 Years
Sex
All
01

Study summary

Columbia 2 is a Phase 2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX) alone and in combination with novel oncology therapies in adjuvant high-risk microsatellite-stable colorectal cancer

Read the detailed description

Columbia 2 is a Phase 2, open-label, randomized, multicenter, platform study of novel oncology therapies in combination with adjuvant chemotherapy in patients with high-risk microsatellite-stable colorectal cancer.

02

Conditions studied

  • Microsatellite-stable Colorectal Cancer

Keywords

  • Microsatellite stable
  • Colon Cancer
  • colorectal cancer
  • MSS-CRC
  • adjuvant
03

In context

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.

Browse Colonic Neoplasms studies →

Lead sponsor

MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.

First submitted after MedImmune LLC became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 101 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written and any locally required authorization obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations.
  2. Age ≥ 18 years at the time of screening
  3. (ECOG) performance status of 0 or 1
  4. proven Stage II or Stage III CRC

    Subjects must also meet the following criteria:

    1. Eligible for 6 months of mFOLFOX6 chemotherapy within 8 weeks after surgery
    2. Must NOT have received prior systemic chemotherapy, immunotherapy, or radiotherapy for treatment of CRC.
    3. Must NOT have defective DNA mismatch repair (MSI) as documented by testing
  5. Margin-negative (R0; defined as >1 mm clearance) surgical resection
  6. Postoperative ctDNA-positive status defined by the presence of ctDNA derived from plasma; determined using a validated assay per protocol
  7. Subjects must have adequate organ function
  8. Body weight > 35 kg
  9. Adequate method of per protocol

Exclusion criteria

Exclusion Criteria:

  1. Any condition that, in the opinion of the investigator, would interfere with evaluation of the product or interpretation of subject safety or study results.
  2. Evidence of disease (including presence of tumor cells in ascites or peritoneal carcinomatosis resected "en bloc").
  3. History of allogeneic organ transplantation.
  4. Active or prior documented disorders within the past 5 years as noted in the protocol.
  5. Cardiac and vascular criteria:

    1. History of venous thrombosis within the past 3 months prior to the scheduled first dose of study treatment.
    2. Presence of acute coronary syndrome including myocardial infarction or unstable angina pectoris, other arterial thrombotic event including cerebrovascular accident or or stroke within the past 6 months prior to the scheduled first dose of study treatment.
    3. (NYHA) Class II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or uncontrolled hypertension.
    4. History of hypertensive crisis/hypertensive encephalopathy within the past 6 months prior to the scheduled first dose of study treatment.
    5. Mean corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms
  6. Uncontrolled intercurrent illness, see the protocol for details.
  7. History of another primary except for: (a) Malignancy treated with curative intent and with no known active disease ≥ 5 years prior to the scheduled first dose of study treatment and of low potential risk for recurrence
  8. History of active primary immunodeficiency.
  9. Active infection including tuberculosis, , , or .
  10. Known allergy or to any of the investigational product or noninvestigational product formulations.
  11. Any condition that, in the opinion of the investigator, would prevent the initiation of 6 months therapy within 8 weeks of surgery
  12. Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment.
  13. Major surgical procedure, open , or significant traumatic injury within 28 days prior to the scheduled first dose of study treatment, or anticipation of the need for major surgical procedure during the course of the study.
  14. Current or prior use of medication within 14 days prior to the scheduled first dose of study treatment.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Control Arm (mFOLFOX6)

    Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).

    Drug: Standard of Care - mFOLFOX6 · Drug: E1 - mFOLFOX and durvalumab · Drug: E2 - mFOLFOX6, durvalumab and oleclumab · Drug: E3 - mFOLFOX6, durvalumab and monalizumab

  • Experimental
    Durvalumab

    Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)

    Drug: E1 - mFOLFOX and durvalumab · Drug: E2 - mFOLFOX6, durvalumab and oleclumab · Drug: E3 - mFOLFOX6, durvalumab and monalizumab

  • Experimental
    Oleclumab

    Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)

    Drug: E2 - mFOLFOX6, durvalumab and oleclumab

  • Experimental
    Monalizumab

    Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)

    Drug: E3 - mFOLFOX6, durvalumab and monalizumab

Interventions

  • DrugStandard of Care - mFOLFOX6

    Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).

    Also known as: FOLFOX (Oxaliplatin, Folinic acid (leucovorin), Fluorouracil (5-FU))

  • DrugE1 - mFOLFOX and durvalumab

    Drug page: Durvalumab

    Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle). Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)

    Also known as: Durvalumab (MEDI-4736)

  • DrugE2 - mFOLFOX6, durvalumab and oleclumab

    Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle). Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)

    Also known as: Durvalumab (MEDI-4736) + Oleclumab (MEDI-9447)

  • DrugE3 - mFOLFOX6, durvalumab and monalizumab

    Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle). Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)

    Also known as: Durvalumab (MEDI-4736) + Monalizumab (IPH2201)

06

What researchers measure

Primary outcomes

  1. ctDNA clearance

    ctDNA clearance is defined as the change from ctDNA positive status at baseline to ctDNA negative post baseline (6 months)

    Time frame: From the time of first dose to 6 months post treatment

Secondary outcomes

  1. Incidence of adverse events

    The secondary endpoint of safety as assessed by the number of subjects with adverse events and serious adverse events

    Time frame: From time of first dose to 90 days post last dose

  2. Disease free survival

    From randomization until time of first documented incidence of disease recurrence, secondary cancer, or death due to any cause, whichever occurs first

    Time frame: From time of first dose till end of study (5 years)

  3. Disease free survival at 12 months

    Percentage of subject who are disease free at 12 months post first dose of treatment

    Time frame: From time of first dose till end of study (5 years)

  4. overall survival

    From randomization until death due to any cause

    Time frame: From time of first dose till end of study (5 years)

  5. Serum conenctration levels of novel agents in combination with mFOLFOX6

    Pharmacokinetics of novel agents in combination with FOLFOX

    Time frame: From Day 1 up to 90 days post last dose

  6. Number of subjects with detectable anti-drug antibody (ADA) to novel agents in combination with mFOLFOX6

    Immunogenicity of novel agents in combination with mFOLFOX6

    Time frame: From Day 1 up to 90 days post last dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2020; primary completion for Mar 2024, 41 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2019
First posted
Oct 30, 2019
StartEst.
Oct 1, 2020
Primary completionEst.
Mar 19, 2024
CompletionEst.
Mar 19, 2024
Last update
Sep 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04145193
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Oct 30, 2019
Start date
Oct 1, 2020 (estimated)
Primary completion
Mar 19, 2024 (estimated)
Completion
Mar 19, 2024 (estimated)
Last update
Sep 21, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion